BMJ Open,
Год журнала:
2020,
Номер
10(8), С. e036663 - e036663
Опубликована: Авг. 1, 2020
Objective
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
the
leading
cause
of
end-stage
diseases
worldwide.
Understanding
NAFLD
prevalence
and
trends
over
time
at
global,
regional
national
levels
critical
to
understanding
burden
creating
more
tailored
prevention
strategies.
Design
Population-based
observational
study.
Setting
The
study
was
including
21
regions
195
countries
or
territories.
Main
outcomes
measure
estimated
annual
percentage
change
for
prevalence.
Results
Worldwide,
cases
have
increased
from
391.2
million
in
1990
882.1
2017,
with
rate
increasing
8.2%
10.9%
during
same
period.
were
consistent
across
sexes.
Case
numbers
highest
East
Asia,
followed
by
South
then
North
Africa
Middle
East.
observed
East,
while
greatest
increase
detected
Western
Europe,
Tropical
Latin
America,
high-income
America.
Conclusion
Nearly
all
territories
worldwide
experienced
a
significant
Oman.
Almost
showed
trend
past
three
decades.
This
drastic
alarming
suggests
that
has
emerged
as
new
public
health
concern
As
such,
efficient
strategies
are
urgently
needed.
Clinical Research in Cardiology,
Год журнала:
2020,
Номер
110(7), С. 921 - 937
Опубликована: Июль 21, 2020
Abstract
Non-alcoholic
fatty
liver
DISEASE
(NAFLD)
is
the
most
common
chronic
disease
in
Western
countries
and
affects
approximately
25%
of
adult
population.
Since
NAFLD
frequently
associated
with
further
metabolic
comorbidities
such
as
obesity,
type
2
diabetes
mellitus,
or
dyslipidemia,
it
generally
considered
hepatic
manifestation
syndrome.
In
addition
to
its
potential
cause
liver-related
morbidity
mortality,
also
subclinical
clinical
cardiovascular
(CVD).
Growing
evidence
indicates
that
patients
are
at
substantial
risk
for
development
hypertension,
coronary
heart
disease,
cardiomyopathy,
cardiac
arrhythmias,
which
clinically
result
increased
mortality.
The
natural
history
variable
vast
majority
will
not
progress
from
simple
steatosis
fibrosis
end
stage
disease.
However,
progressive
forms
NAFLD,
including
non-alcoholic
steatohepatitis
(NASH)
and/or
advanced
fibrosis,
well
concomitant
types
highest
CVD.
This
review
describes
underlying
pathophysiological
mechanisms
linking
CVD,
discusses
role
a
dysfunction
factor,
focuses
on
manifestations
patients.
